Advertisement
UK markets closed
  • FTSE 100

    7,952.62
    +20.64 (+0.26%)
     
  • FTSE 250

    19,884.73
    +74.07 (+0.37%)
     
  • AIM

    743.26
    +1.15 (+0.15%)
     
  • GBP/EUR

    1.1701
    +0.0007 (+0.06%)
     
  • GBP/USD

    1.2637
    +0.0015 (+0.12%)
     
  • Bitcoin GBP

    55,699.50
    -436.43 (-0.78%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • S&P 500

    5,254.35
    +5.86 (+0.11%)
     
  • DOW

    39,807.37
    +47.29 (+0.12%)
     
  • CRUDE OIL

    83.11
    -0.06 (-0.07%)
     
  • GOLD FUTURES

    2,254.80
    +16.40 (+0.73%)
     
  • NIKKEI 225

    40,369.44
    +201.37 (+0.50%)
     
  • HANG SENG

    16,541.42
    +148.58 (+0.91%)
     
  • DAX

    18,492.49
    +15.40 (+0.08%)
     
  • CAC 40

    8,205.81
    +1.00 (+0.01%)
     

Small Molecule Innovator CDMO Global Market Report 2023: Increasing Demand for Small Molecule Drugs Bolsters Sector

Company Logo
Company Logo

Global Small Molecule Innovator CDMO Market

Global Small Molecule Innovator CDMO Market
Global Small Molecule Innovator CDMO Market

Dublin, March 15, 2023 (GLOBE NEWSWIRE) -- The "Small Molecule Innovator CDMO Market Size, Share & Trends Analysis Report By Product (Small Molecule API, Small Molecule Drug Product), By Stage Type, By Customer Type, By Therapeutic Area, By Region, And Segment Forecasts, 2023 - 2030" report has been added to ResearchAndMarkets.com's offering.

The global small molecule innovator CDMO market size is expected to reach USD 74.9 billion by 2030, expanding at 6.4% CAGR from 2023 to 2030.

There is a growing interest among pharmaceutical companies in outsourcing to support core competencies such as sales, marketing, and others, due to associated cost savings.

ADVERTISEMENT

Furthermore, outsourcing enables companies to further progress core competencies such as drug development and manufacturing activities. Hence, expansions by small molecule CDMOs in recent years promise major support for the market growth in the upcoming years.

Small molecules continue to play an important role in the development of new treatments globally. Specialty medicines are increasingly driving global pharmaceutical manufacturing growth, particularly in developed markets with small molecule application accounting for over half of specialty sales. The application of small molecules are becoming increasingly complex.

The majority of solutions in the regulatory approval pipeline are made up of poorly soluble compounds that would require enabling technology to progress to clinical trials and beyond. As therapy targets and focus areas become more specific, creating target product profiles has become increasingly difficult. Failure to achieve appropriate bioavailability is an additional stumbling block in the development of many new chemical entities. These factors are expected to support the overall market growth.

The geriatric population is expected to witness a surge in the coming years. For instance, the WHO estimates that there will be more than 2 billion people aged 60 and over by 2050. This would create a lot of opportunities for the development of new small-molecule drugs, which is expected to support the market growth in the post-pandemic period.

Market Dynamics

Market Drivers

  • Increasing Demand for Small Molecule Drugs

  • Growing Demand for Small Molecules in the Oncology Segment

  • Increasing Pharmaceutical R&D Investments

Market Restraints

  • Stringent Government Regulations

  • Compliance Issues with Outsourcing

Small Molecule Innovator CDMO Market Report Highlights

  • The small molecule API segment is anticipated to register the fastest CAGR of 6.7% over the forecast period. This growth can primarily be attributed to the high approval rate of NME small molecules by regulatory agencies

  • The clinical stage segment dominated the market with 55.1% of the revenue share in 2022. CDMOs offer specialized expertise, time-saving, and cost-efficiency during clinical procedures. This is expected to augment the segmental growth over the forecast period

  • Based on customer type, the pharmaceutical companies segment held the largest share of 93.9% in 2022. The growing focus on pharmaceutical companies to focus on core competencies, such as sales and adoption of expansion strategies by CDMOs for manufacturing small molecule drugs, are promoting the segment's market growth

  • The oncology segment dominated the market with 41.8% of the revenue share in 2022, and it is anticipated to register the fastest CAGR of over 7.0% over the forecast period. A significant number of oncology drugs in the regulatory approval pipeline is one of the major factors supporting the segment's growth

  • Asia Pacific is anticipated to register the fastest CAGR of 7.2% over the forecast period. Due to significantly cheaper manufacturing costs than in North America & Europe and favorable regulations guiding innovation

Key Attributes:

Report Attribute

Details

No. of Pages

119

Forecast Period

2022 - 2030

Estimated Market Value (USD) in 2022

$45.2 Billion

Forecasted Market Value (USD) by 2030

$74.9 Billion

Compound Annual Growth Rate

6.4%

Regions Covered

Global

Key Topics Covered:

Chapter 1 Methodology and Scope

Chapter 2 Executive Summary

Chapter 3 Small Molecule Innovators CDMO Market: Variables, Trends, & Scope

Chapter 4 Small Molecule Innovator CDMO Market: Product Segment Analysis
4.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
4.2 Small Molecule API
4.3 Small Molecule Drug Product
4.3.2 Oral Solid Dose
4.3.3 Semi-Solid Dose
4.3.4 Liquid Dose
4.3.5 Others

Chapter 5 Small Molecule Innovators CDMO Market: Stage Type Segment Analysis
5.1 Small Molecule Innovators Cdmo: Market Share Analysis, 2022 & 2030
5.2 Preclinical
5.2.1 Preclinical Market, 2018 - 2030 (USD Billion)
5.3 Clinical
5.3.2 Phase I
5.3.2.2 Small
5.3.2.3 Medium
5.3.2.4 Large
5.3.3 Phase II
5.3.4 Phase III
5.4 Commercial

Chapter 6 Small Molecule Innovators CDMO Market: Customer Type Segment Analysis
6.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
6.2 Pharmaceutical
6.2.1 Pharmaceutical Market, 2018 - 2030 (USD Million)
6.2.2 Small
6.2.2.1 Small Market, 2018 - 2030 (USD Million)
6.2.3 Medium
6.2.3.1 Medium Market, 2018 - 2030 (USD Million)
6.2.4 Large
6.2.4.1 Large Market, 2018 - 2030 (USD Million)
6.3 Biotechnology
6.3.1 Biotechnology Market, 2018 - 2030 (USD Million)

Chapter 7 Small Molecule Innovators CDMO Market: Therapeutic Area Segment Analysis
7.1 Small Molecule Innovators CDMO: Market Share Analysis, 2022 & 2030
7.2 Cardiovascular Disease
7.3 Oncology
7.4 Respiratory Disorders
7.5 Neurology
7.6 Metabolic Disorders
7.7 Infectious Diseases
7.8 Others

Chapter 8 Small Molecule Innovators CDMO Market: Regional Analysis

Chapter 9 Competitive Landscape

Companies Mentioned

  • Lonza

  • Patheon (Thermo Fisher Scientific)

  • Cambrex Corporation

  • Catalent, Inc

  • Siegfried Holding AG

  • Recipharm AB

  • CordenPharma International

  • Boehringer ingelheim

  • Piramal Pharma Solutions

  • Labcorp Drug Development

For more information about this report visit https://www.researchandmarkets.com/r/9kautc

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Attachment

CONTACT: CONTACT: ResearchAndMarkets.com Laura Wood,Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900